Pfizer Logo

Pfizer Appoints Mikael Dolsten President Of Worldwide Research And Development

Tuesday, May 25, 2010 - 09:30pm

Company Concludes its Integration of Research Functions

"We have great skills in science, we have industry-leading technologies, and I am very proud of our R&D pipeline. I look forward to working with our leaders to advance our effort to become the world's premier biopharmaceutical R&D group."

(BUSINESS WIRE)--Today, Pfizer Inc. named Mikael Dolsten, M.D., PhD, President of Pfizer Worldwide Research and Development, as the Company completes its integration of these functions following the Wyeth acquisition. Dr. Dolsten previously led Wyeth's Research and Development organization from May 2008, and after the close of the Wyeth acquisition was named President of Pfizer's BioTherapeutics Research & Development. Prior to his appointment at Wyeth, Dr. Dolsten held key leadership roles in R&D at Boehringer Ingelheim and AstraZeneca.

With this appointment, Dr. Dolsten will now lead all of research at Pfizer, as well as development of all compounds through Phase 2, or 'proof of concept.' Late-stage clinical development will continue to be led by clinical teams throughout the Worldwide Biopharmaceutical Businesses, as announced in April 2009.

"Since closing the Wyeth acquisition we have rapidly advanced integration, completing the pipeline portfolio review, finalizing decisions regarding our R&D network very quickly after close, and steadily progressing the pipeline. Rapid integration has been enhanced by strong and steady collaboration between the two legacy R&D groups -- making the consolidation under one leader a natural and progressive step to take at this point," said Jeffrey Kindler, Pfizer's chairman and chief executive officer.

The newly named Pfizer Worldwide Research & Development organization will maintain an R&D structure that supports excellence in small molecules, large molecules and vaccine research and development. It will include biotherapeutics research and development, focused on large molecules and biotechnologies; pharmatherapeutics research and development, focused on small molecules; and vaccines research and development. Pfizer adopted a novel R&D model following the Wyeth acquisition to foster diversity of talent, assets and culture, as well as the empowerment and accountability of research leaders across R&D. Pfizer initially implemented this model with a two-division structure (BioTherapeutics and PharmaTherapeutics) to ensure the progress and steady integration of both legacy organizations. Due to the speed and effectiveness of the integration, Pfizer is now able to implement a diversified R&D platform with the same breadth and research programs, under the consolidated leadership of Dr. Dolsten.

"Mikael Dolsten is an exceptional scientist who is highly regarded and committed to bringing new preventative measures, treatments and cures to people. Mikael's scientific expertise, vision for R&D and commercial mindset have distinguished him at Pfizer and uniquely qualify him to lead our R&D colleagues and advance our pipeline. Having all of Pfizer's research conducted under Mikael's leadership will enrich the alignment between our

research programs and commercial teams to address important unmet medical needs and deliver the next generation of medicines," said Mr. Kindler.

"I am excited to have the opportunity to align the tremendous science that is in every corner of Pfizer to bring forward medicines and vaccines that transform lives," said Dr. Dolsten. "We have great skills in science, we have industry-leading technologies, and I am very proud of our R&D pipeline. I look forward to working with our leaders to advance our effort to become the world's premier biopharmaceutical R&D group."

Pfizer also announced today the resignation of Martin Mackay, President, PharmaTherapeutics Research & Development, who will leave the company effective immediately. Dr. Dolsten will expand the role of Rod MacKenzie, PhD, who is currently Senior Vice President and Head of Worldwide Research for PharmaTherapeutics R&D. In addition to his current responsibilities leading small molecule research, Dr. MacKenzie will add responsibility for Asia R&D strategy, as well as small molecules pharmaceutical science.

"We thank Martin Mackay for his many accomplishments and greatly appreciate all he has done to help us develop world-class scientists at Pfizer," added Mr. Kindler. "I know Mikael will work closely with Rod and all of our leaders across PharmaTherapeutics and BioTherapeutics to ensure continuity of strategy and progress, as we continue to build our science base at Pfizer," said Mr. Kindler.

"Rod's ability to transform pharmaceutical research has impressed me tremendously," said Dr. Dolsten. "I am excited he has accepted to take on an expanded new role, and I look forward to a strong partnership to advance Pfizer R&D - and to serve people who rely on science and medicine for healthier and more productive lives."

Pfizer Inc: Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more about our commitments, please visit us at www.pfizer.com

Pfizer Inc. Media: Ray Kerins, 212-733-9203 Investors: Charles E. Triano, 212- 733-3901